Replies to post #5251 on Dendreon Corp fka DNDNQ

[iwfal]

The subset of patients in these two trials who received the doses comparable to the Phase 3 dose showed median survival of 34.9 months and 35.0 months, respectively.

I would assume that they picked the max dose to carry forward into the ph iii? Did they release a p value for efficacy vs dose trend in pre-defined dose subgroups?


Did they release the size of that subpopulation with the 34.9 and 35.0 months median survival (one of them was ~22 patients, the other much smaller?)?


And note that CEGE PR is EXTREMELY suspect. On a 1=Trustworthiness of Abraham Lincoln, 10=CTIC (Dendreon being about a 6 or 7 - typical biotech) then CEGE is about a 9. See the following PR (since pulled if I remember correctly).

http://investorshub.advfn.com/boards/read_msg.asp?message_id=11878496

All in all, not particularly confidence inspiring.

Clark